- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03271710
Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System (ENTRAP)
A Single-Arm, Multicenter Study for the Lower Extremities Using the Vanguard IEP Peripheral Balloon Angioplasty System With Integrated Embolic Protection
Study Overview
Status
Intervention / Treatment
Detailed Description
The ENTRAP Study is a prospective, multi-center, non-randomized, single-arm, study with follow-up to 30 days to determine the acute safety, acute device performance and clinical performance of the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection. The Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection is indicated for peripheral vascular percutaneous transluminal angioplasty (PTA) and capture and removal of embolic material during angioplasty for the femoral, iliac, popliteal and profunda arteries.
The Vanguard System has been designed to revascularize iliac and femoro-popliteal PAD while protecting against embolization at the same time. It is the first system in which the embolic protection filter is coupled on the same catheter as the angioplasty balloon for use in the lower extremities. Up to 130 patients will be enrolled into this study and followed for 30 days after post-procedure. Adult patients with lifestyle-limiting claudication or rest pain (Rutherford categories 2 to 3) who meet all eligibility criteria will be approached for participation in the trial.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aalst, Belgium, 9300
- OLV Hospital Aalst
-
Bonheiden, Belgium, 2820
- Imelda Hospital / Vascular Science Research Center
-
Dendermonde, Belgium, 9300
- AZ Sint Blasius
-
Tienen, Belgium, 3300
- RZ Heilig Hart Hospital
-
-
-
-
-
Bad Krozingen, Germany, 79189
- Interventional Cardiology and Vascular Medicine, Department of Angiology, Universitäts-Herzzentrum Freiburg
-
Berlin, Germany, 10713
- Sankt Gertrauden-Krankenhaus
-
Flensburg, Germany, 24939
- Daikonissenkrankenhaus Flensburg
-
Hamburg, Germany
- MVZ/Prof. Mathey Prof. Schofer Clinic
-
Leipzig, Germany, 04103
- Universitätsklinikum Leipzig
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients ≥18 years old.
- Subject has clinically significant symptomatic leg ischemia requiring treatment.
- Subject has a Rutherford category of 2 - 3.
- Target lesion in the superficial femoral artery (SFA), common femoral artery, p1 segment of popliteal artery, common iliac artery and external iliac artery (cross-over access only), and profunda femoris arteries.
- Target lesion stenosis >50% by investigator's visual estimate.
- Vessel diameter between 4.0 mm and 8.0 mm at the site of the target lesion.
- Total target lesion length ≤ 18 cm, and may include a chronic total occlusion ≤ 10 cm.
- If target lesion is restenotic, the prior PTA must be > 30 days prior to enrollment.
- If the guide wire traverses the lesion subintimally, it must enter the true lumen distal to the lesion without the use of a reentry device.
- Distal vessel diameter at the site of filter deployment of 4.0 mm to 8.0 mm with sufficient landing zone required for the successful deployment of the integrated embolic protection filter.
- Patent popliteal and infrapopliteal arteries; I.e. single vessel runoff or better with at least one of three vessels patient (<50% stenosis) to the ankle or foot.
- The patient (or legally authorized representative) is willing to provide written informed consent and to comply with all study requirements.
Exclusion Criteria:
- Subjects who have undergone prior vascular surgery of the target artery to treat atherosclerotic disease.
- History of major amputation in the same limb as the target lesion.
- Woman who is pregnant or nursing.
- Subject has Rutherford category of 4- 6.
- Target lesion(s) within native or synthetic vessel grafts.
- Use of atherectomy as an adjunctive therapy during the index procedure in the target lesion or target vessel.
- Any major (e.g. cardiac, peripheral, abdominal) intervention, including in the contralateral lim planned within 30 days post index procedure.
- Presence of other hemodynamically significant outflow lesion in the target limb requiring intervention within 30 days of enrollment.
- Subject has significant inflow disease which cannot be treated prior to target lesion treatment.
- Presence of aneurysm in the target vessel.
- Acute limb occlusion due to thrombotic occlusion of the target limb.
- In-stent restenosis of target lesion.
- Severe calcification that renders the target lesion lesion resistant to angioplasty.
- Visible acute thrombus in the target lesion
- Intolerance to antiplatelet, anticoagulant or thrombolytic therapy medications that would be administered during the trial.
- Known hypersensitivity to contrast media that cannot be adequately premedicated.
- Known hypersensitivity to nickel and/or titanium.
- Acute Myocardial Infarction within 30 days prior to the index procedure.
- Subject has a known coagulopathy or bleeding diathesis, or INR <1.5.
- Platelet count <100,000 mm3/L or >700,000 mm3/L
- Concomitant renal failure with a serum creatinine > 2.5 mg/dL or receiving dialysis.
- Patient is currently participating in an interventional study, investigational drug or device study that has not completed the primary endpoint, that may potentially confound the results of this trial or that would limit the subject's compliance with the follow-up requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Peripheral balloon angioplasty
Peripheral vascular percutaneous transluminal angioplasty (PTA) and capture and removal of embolic material during angioplasty for the femoral, iliac, popliteal and profunda arteries with the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection
|
Percutaneous transluminal angioplasty (PTA) of the lower extremities
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from MAE, defined as death, amputation and target vessel revascularization (TVR)
Time Frame: 30 days
|
Primary safety endpoint
|
30 days
|
Procedural success
Time Frame: 24 hours or at discharge.
|
Defined as <50% residual stenosis without MAE (death, amputation or TVR)
|
24 hours or at discharge.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Success
Time Frame: Index procedure
|
Technical success of the investigational device using questionnaire
|
Index procedure
|
Ankle-Brachial Index (ABI)
Time Frame: Baseline, discharge and 30 days
|
Change in Ankle-Brachial Index from baseline, discharge and 30 days
|
Baseline, discharge and 30 days
|
Rutherford-Becker
Time Frame: 30 days
|
Rutherford-Becker improvement greater than or equal to 1
|
30 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Histomorphometric analysis of embolic protection filter content
Time Frame: Day 0. Filter collected at end of index procedure.
|
Histomorphometric analysis of embolic protection filter content
|
Day 0. Filter collected at end of index procedure.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas Zeller, Prof., Universitats-Herzzentrum Freiburg
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSP1121
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on peripheral balloon angioplasty
-
Henry Ford Health SystemBoston Scientific CorporationWithdrawn
-
Konkuk University Medical CenterUnknownVascular Graft Anastomotic Stenosis
-
Vienna General HospitalCompletedInstent Restenosis | Cutting Balloon AngioplastyAustria
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaCompletedCoronary VesselsKorea, Republic of
-
TriReme Medical, LLCUniversity Hospitals Cleveland Medical CenterWithdrawnInfrainguinal Peripheral Arterial DiseaseUnited States
-
Centre Hospitalier Universitaire de NīmesTerminatedFistula | Arteriovenous FistulaFrance
-
King Faisal Specialist Hospital & Research CenterUnknownStenosis of Arteriovenous Dialysis FistulaSaudi Arabia
-
Cantonal Hospital of St. GallenUnknownRenal InsufficiencySwitzerland
-
Seung-Jung ParkCardioVascular Research Foundation, Korea; B. Braun Korea Co., Ltd.RecruitingCoronary Artery Disease | Angioplasty, BalloonKorea, Republic of
-
University Health Network, TorontoThe Hospital for Sick ChildrenUnknownCoronary Artery Disease